Clinical Trial Update: A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brigatinib in ALK-positive NSCLC patients previously treated with crizotinib has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AP26113 (brigatinib)
• Brigatinib (brigatinib)

Snippet

Sponsor: Ariad Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2017-06-21